Finding new treatments for Alzheimer's disease by studying protein interactions with cell membranes

A cost-effective, high-throughput screening platform for modulator discovery of a-synuclein membrane interactions involved in neurodegenerative diseases

['FUNDING_R21'] · UNIVERSITY OF VIRGINIA · NIH-11010453

This study is looking at how a protein linked to Alzheimer's disease interacts with cell membranes, and it's trying to find new ways to help people by discovering compounds that could reduce the harmful effects of that protein.

Quick facts

Phase['FUNDING_R21']
Study typeNih_funding
SexAll
SponsorUNIVERSITY OF VIRGINIA (nih funded)
Locations1 site (CHARLOTTESVILLE, UNITED STATES)
Trial IDNIH-11010453 on ClinicalTrials.gov

What this research studies

This research focuses on understanding how a protein called α-synuclein interacts with cell membranes, which is believed to contribute to Alzheimer's disease and related dementias. Researchers have developed innovative tools to observe these interactions in detail, aiming to discover new compounds that can modify or inhibit the harmful effects of α-synuclein. By identifying potential therapeutic agents, this research hopes to provide new avenues for treatment that could improve the lives of those affected by these neurodegenerative diseases.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or related dementias.

Not a fit: Patients with neurodegenerative diseases not related to Alzheimer's or those without any cognitive impairments may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to new therapies that slow down or prevent the progression of Alzheimer's disease.

How similar studies have performed: Previous research has shown promise in targeting protein interactions in neurodegenerative diseases, suggesting that this approach could yield valuable insights and potential breakthroughs.

Where this research is happening

CHARLOTTESVILLE, UNITED STATES

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.

View on NIH RePORTER →

Conditions: Alzheimer disease dementia, Alzheimer syndrome

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.